Abstract:Ulcerative colitis (UC), a major type of inflammatory bowel disease, is also a chronic non-specific intestinal inflammation condition of unknown etiology. The pathogenesis of UC is closely associated with immune abnormalities, inflammatory damage and genetics. The present study aimed to explore the effects of microRNA (miR)-21-5p on the interleukin-6 (IL-6) receptor (IL6R)/signal transducer and activator of transcription (STAT3) signal pathway in UC, in order to identify a highly effective treatment for UC. A total of 45 patients with UC and 45 healthy controls were recruited for the present study. The expression levels of miR-21-5p and STAT3 in the sera of patients with UC and healthy controls were determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). A UC rat model was established using dextran sulfate sodium. Following lipopolysaccharide (LPS) treatment, RAW264.7 cells were transfected with a miR-21-5p inhibitor. The levels of morphological damage and apoptosis of the colonic mucosal epithelial tissue were investigated using hematoxylin and eosin staining and a TUNEL staining assay, and then the colon macroscopic damage index and disease activity index were measured in rats. Western blot analysis was used to detect the protein expression levels of IL6R, STAT3, intracellular adhesion molecule 1 (ICAM-1), NF-κB, cleaved caspase-3, cleaved caspase-9 and Fas ligand (FasL). RT-qPCR detected the mRNA expression levels of miR-21-5p, IL6R, STAT3, ICAM-1, NF-κB, caspase-3, caspase-9 and FasL. An ELISA was performed to measure the levels of inflammatory cytokines. The viability and apoptosis levels of RAW264.7 cells were examined using MTT and flow cytometry assays. Additionally, STAT3 was investigated as a direct target of miR-21-5p in RAW264.7 cells using a dual-luciferase reporter assay. The results of the present study demonstrated that inflammation and apoptotic markers were revealed to be significantly downregulated following transfection with miR-21-5p inhibitors in RAW264.7 cells induced by LPS, and that cell viability was increased. Furthermore, STAT3 was confirmed to be a target of miR-21-5p in RAW264.7 cells. Collectively, these data demonstrated that miR-21-5p inhibition mediated the IL-6/STAT3 pathway in UC rats to decrease the levels of inflammation and apoptosis in RAW264.7 cells, and suggested that miR-21-5p may be an important therapy target in human UC.

Expression of Interleukin-22/Stat3 Signaling Pathway in Ulcerative Colitis and Related Carcinogenesis

Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.

IL-22 is related to development of human colon cancer by activation of STAT3

Expression of Irak-3 is Associated with Colitis-Associated Tumorigenesis in Mice

Increased Expression of Interleukin-23 Induces Proinflammatory Cytokine Secretion in Inflammatory Bowel Disease

Significance of interleukin-27 expression in the intestinal mucosa of patients with inflammatory bowel disease

Role of Interleukin-22 in ulcerative colitis

The Expression of Interleukin-23 Receptor and Interleukin-17a in Patients with Inflammatory Bowel Disease and its Clinical Significance

The Expressions of IL-2, IL-4, IL-17 and IL-10 in Ulcerative Colitis (UC) Mucosa and Its Relation with Disease Activity

Immune Regulation of Interleukin-23 on Peripheral Blood Natural Killer Cell in Patients with Inflammatory Bowel Disease

The Increased Expression of IL-23 in Inflammatory Bowel Disease Promotes Intraepithelial and Lamina Propria Lymphocyte Inflammatory Responses and Cytotoxicity.

The expression of leptin in human ulcerative colitis and its role in pathogenesis

S1733 the Role of the IL-6/STAT3/SOCS3 Pathway in Ulcerative Colitis Related Carcinogenesis

Expression of IL-17 and STAT3 in colorectal cancer tissue and its clinical significance

The Role of the Mir-21-5p-mediated Inflammatory Pathway in Ulcerative Colitis

PI3K/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis

The Expression of HBD-2, NF-kB, IL-6 and IL-23 in Colonic Mucosa of Ulcerative Colitis and Irritable Bowel Syndrome

Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.

High Suppressor Of Cytokine Signaling-3 Expression Impairs Stat3-Dependent Protective Effects Of Interleukin-22 In Ulcerative Colitis In Remission

IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy